Johnson & Johnson has received United States Food and Drug Administration approval for its Dual Energy ThermoCool SmartTouch SF platform, expanding the company’s cardiac ablation portfolio with a single-catheter system that can deliver both radiofrequency energy and pulsed field energy during electrophysiology procedures. The approval gives physicians in the United States access to a dual-energy ablation platform integrated with the company’s CARTO mapping ecosystem.
The device is designed for cardiac ablation procedures in which electrophysiologists destroy or isolate abnormal heart tissue that contributes to arrhythmias. By combining radiofrequency and pulsed field capability in one familiar catheter platform, Johnson & Johnson is positioning the technology as a more flexible option for complex cases where anatomy, tissue characteristics and treatment goals can vary from patient to patient.
The approval is commercially important because pulsed field ablation has become one of the most closely watched areas in electrophysiology. It also gives Johnson & Johnson a sharper competitive answer in a cardiac rhythm market where medtech companies are racing to combine safety, speed, precision and workflow efficiency. The first United States procedures with the platform are expected to begin this summer through a phased commercial rollout.
What has the United States Food and Drug Administration approved for Johnson & Johnson?
The United States Food and Drug Administration has approved the Dual Energy ThermoCool SmartTouch SF platform, an integrated catheter ablation system that allows electrophysiologists to use radiofrequency energy and pulsed field energy through a single catheter. The platform builds on the established ThermoCool SmartTouch SF catheter family, which Johnson & Johnson says has been used to treat more than one million patients in the United States.
The approval follows the earlier European introduction of the technology and allows Johnson & Johnson to expand access in the United States. For physicians, the main change is procedural flexibility. Instead of choosing one energy modality before the case and remaining locked into that approach, the system gives operators access to two ablation energy types from the same platform.
The device is also integrated with the CARTO ecosystem, which is used for three-dimensional electroanatomical mapping, imaging support and procedural guidance. Integration matters because cardiac ablation is not only about the catheter tip. It also depends on accurate mapping, lesion planning, contact force information and the ability to reproduce effective workflows across different patients and sites.
The regulatory decision does not mean every arrhythmia patient will need dual-energy ablation. It means physicians now have another approved tool that can be selected according to clinical judgement, anatomy and case complexity.
Why does a single catheter with radiofrequency and pulsed field energy matter?
Radiofrequency ablation has been a cornerstone of electrophysiology for decades. It works by using thermal energy to heat targeted tissue and create lesions that interrupt abnormal electrical pathways. The approach is familiar, widely used and supported by extensive clinical experience, but thermal ablation can require careful control to avoid damage to surrounding structures.
Pulsed field ablation uses short electrical pulses to create pores in cell membranes through a process known as electroporation. One of the reasons the field has attracted so much interest is the potential for greater tissue selectivity, particularly in cardiac tissue, which may help reduce certain risks associated with thermal injury.
A dual-energy catheter gives physicians the ability to choose the energy type that best fits the anatomical target and procedural objective. In some areas, pulsed field energy may be attractive because of its non-thermal mechanism. In other areas, radiofrequency energy may remain useful because of operator familiarity, lesion control or the specific tissue substrate being treated.
The value proposition is therefore not simply that one energy type is replacing another. Johnson & Johnson is arguing that both may be useful within the same procedural ecosystem, especially in cases where anatomy or arrhythmia substrate is not straightforward.
How could the platform change electrophysiology workflow in atrial fibrillation care?
Atrial fibrillation is one of the largest drivers of cardiac ablation demand. The condition occurs when abnormal electrical activity disrupts the heart’s normal rhythm, increasing the risk of symptoms such as palpitations, fatigue, shortness of breath and reduced exercise capacity. In some patients, atrial fibrillation also raises the risk of stroke and heart failure complications.
Catheter ablation is commonly used when rhythm-control medicines are ineffective, poorly tolerated or unsuitable. Pulmonary vein isolation is a central strategy because abnormal electrical triggers often originate around the pulmonary veins. The challenge is creating durable lesions while reducing complications and maintaining efficient procedural flow.
The Dual Energy ThermoCool SmartTouch SF platform could support electrophysiologists by allowing energy selection within a mapped and guided procedural environment. The combination of contact force information, CARTO mapping and dual-energy capability may help physicians plan and execute ablation more confidently.
Workflow familiarity is also commercially important. New ablation technologies can face adoption barriers when physicians must learn entirely new systems, retrain teams or change lab logistics. By building the dual-energy option onto a catheter platform and mapping ecosystem already known to many electrophysiologists, Johnson & Johnson may reduce some of the friction that usually comes with a new cardiac device launch.
Why is pulsed field ablation becoming such a competitive area in medtech?
Pulsed field ablation has become a major medtech battleground because it promises to address several limitations of conventional thermal ablation. The attraction is not just clinical. It is also commercial, because atrial fibrillation is common, ablation volumes are growing and hospitals continue to invest in technologies that can improve procedural efficiency and outcomes.
The technology has drawn strong interest because non-thermal energy may reduce the risk of damage to structures near the heart, although real-world safety depends on the specific device, waveform, delivery method, operator technique and patient anatomy. Companies developing pulsed field systems must show not only that their devices can isolate target tissue, but also that they can produce durable results without creating new procedural risks.
Johnson & Johnson’s dual-energy approach is notable because it does not present pulsed field ablation as a standalone replacement for radiofrequency ablation. Instead, it embeds pulsed field capability into a broader ablation platform. This could appeal to electrophysiologists who want innovation without losing access to the radiofrequency tools they already know.
The competitive pressure is real. Boston Scientific, Medtronic, Abbott Laboratories and other electrophysiology players are all seeking stronger positions in atrial fibrillation and cardiac rhythm management. Johnson & Johnson’s approval strengthens its hand in a market where device differentiation increasingly depends on mapping integration, procedural efficiency and evidence-backed safety.
What role does the CARTO ecosystem play in the platform’s clinical positioning?
The CARTO ecosystem is central to Johnson & Johnson’s electrophysiology strategy. Mapping systems help physicians understand the electrical anatomy of the heart, identify abnormal conduction patterns and guide catheter placement. In complex ablation cases, accurate mapping can influence procedure planning and lesion delivery.
Integration with CARTO gives the Dual Energy ThermoCool SmartTouch SF platform a built-in workflow advantage for hospitals already using Johnson & Johnson’s electrophysiology infrastructure. The company said the platform includes advanced mapping, imaging and pulsed field index guidance, while also supporting contact force monitoring.
Contact force matters because lesion quality can depend on how effectively the catheter tip contacts tissue. Too little contact may produce incomplete lesions, while excessive force can increase procedural risk. Guidance tools cannot eliminate the need for operator skill, but they can give physicians more information during ablation.
This integrated model is part of a broader medtech trend. Device companies are increasingly trying to sell systems rather than isolated products. The commercial winner is often not just the company with the best catheter, but the company with the best combination of mapping, software, workflow, training, evidence and service support.
What clinical evidence supports the dual-energy ablation strategy?
Johnson & Johnson has pointed to clinical work evaluating dual-energy focal ablation technology integrated with a three-dimensional mapping system. Early European experience supported the company’s confidence in expanding the platform to the United States, and the FDA approval provides regulatory validation for the submitted safety and effectiveness package.
The broader ThermoCool SmartTouch SF platform also has a long clinical history, which may support physician confidence in the catheter’s handling and workflow. The new approval adds pulsed field capability to a platform that many electrophysiologists already understand.
That said, the commercial and clinical burden now shifts to real-world United States use. Physicians will want to know how the platform performs across paroxysmal and persistent atrial fibrillation, redo procedures, difficult anatomies and higher-risk patient groups. They will also assess procedure time, fluoroscopy use, lesion durability, acute success, recurrence rates and complication patterns.
Approval is a major step, but adoption in electrophysiology is often shaped by accumulated operator experience. The more cases physicians perform with a device, the clearer its practical strengths and limitations become.
What risks and limitations should clinicians consider with dual-energy ablation?
The availability of two energy types does not automatically simplify every procedure. It may add decision-making complexity because physicians must determine when to use radiofrequency energy, when to use pulsed field energy and how to interpret procedural feedback across both modalities.
Pulsed field ablation also has its own learning curve. While it is often discussed as potentially safer for certain tissue interactions, it still requires careful attention to dosing, catheter position, cardiac anatomy and procedural endpoints. Any new energy platform must be evaluated for acute procedural safety as well as longer-term rhythm outcomes.
Radiofrequency energy remains effective but carries known thermal considerations. Physicians must continue to manage risks such as collateral tissue injury, steam pops, thrombus formation, vascular complications and recurrence from incomplete lesions. Dual-energy capability does not remove the need for disciplined technique.
Hospitals will also consider cost, training requirements, inventory management and compatibility with existing lab workflows. A new platform may offer clinical advantages, but procurement committees often need economic justification before broad adoption.
What does the approval mean for Johnson & Johnson’s medtech growth strategy?
For Johnson & Johnson, the approval reinforces the importance of electrophysiology within its medtech business. The company has been investing heavily in cardiovascular technologies, including mapping, navigation, ablation, heart recovery and circulatory restoration. Dual-energy ablation adds another layer to that strategy.
The platform could help Johnson & Johnson defend and expand its position in a high-growth part of cardiovascular care. Atrial fibrillation prevalence is increasing as populations age, diagnosis improves and more patients become eligible for rhythm-control procedures. That makes electrophysiology a strategically attractive market for large medical device companies.
As of July 8, 2026, Johnson & Johnson shares were trading around $267.24, close to the upper end of a 52-week range near $154.80 to $269.43. The stock had gained roughly 6% over five trading days and about 18% over one month, reflecting broadly constructive investor sentiment around the diversified healthcare company rather than this device approval alone.
The dual-energy ablation approval is unlikely to change Johnson & Johnson’s financial profile by itself because the company has a very large revenue base across Innovative Medicine and MedTech. However, it supports the investor narrative that the medtech segment continues to refresh its portfolio with higher-technology platforms in attractive procedural categories.
How could the phased United States rollout shape early adoption?
Johnson & Johnson expects first United States procedures with the Dual Energy ThermoCool SmartTouch SF platform to begin this summer. A phased rollout is a sensible approach because advanced electrophysiology systems require physician training, lab team preparation and careful early case selection.
Initial users are likely to include experienced electrophysiologists and centres already familiar with Johnson & Johnson’s CARTO ecosystem. These sites can provide early feedback on workflow, usability, energy selection and procedural efficiency. Their experience may influence broader adoption as the company expands availability.
A phased launch also allows Johnson & Johnson to manage supply, training and support while collecting real-world insights. For a device that combines two energy modalities, early implementation quality matters. A rushed rollout could create avoidable confusion, while a controlled launch can help physicians build confidence.
The company’s ability to support electrophysiology teams will be important. Device adoption often depends not only on the technology but also on education, clinical specialists, technical support and the ability to troubleshoot in busy procedure rooms.
What is the expert assessment of Johnson & Johnson’s dual-energy ablation approval?
The FDA approval of the Dual Energy ThermoCool SmartTouch SF platform is a meaningful medtech milestone because it gives electrophysiologists a single-catheter system that combines the established utility of radiofrequency ablation with the fast-growing promise of pulsed field ablation. The integration with CARTO strengthens the platform’s clinical and commercial appeal by placing dual-energy delivery inside a familiar mapping and workflow environment.
The approval is especially important because the electrophysiology market is moving quickly. Pulsed field ablation is no longer an experimental curiosity. It is becoming a major competitive axis in atrial fibrillation care, and large medtech companies are racing to define how the technology should be used in real-world practice.
Johnson & Johnson’s strategy is pragmatic. Rather than forcing physicians to choose between old and new energy models, the company is offering both through one catheter platform. That could make sense for complex cases where anatomy, substrate and procedural goals vary.
The caution is that dual capability must translate into better workflow, safety, efficiency or outcomes. Hospitals and physicians will not adopt the platform broadly simply because it is versatile. They will need evidence that the versatility improves decision-making and procedure performance in meaningful ways.
For now, Johnson & Johnson has secured a stronger position in one of cardiovascular medtech’s hottest categories. The next test will come in United States electrophysiology labs, where early procedural experience will determine whether dual-energy ablation becomes a routine advantage or remains a premium tool for selected complex cases.
